AveXis said that a one-time infusion of Zolgensma (onasemnogene abeparvovec-xioi) delivered rapid, substantial, and clinically meaningful therapeutic benefit in spinal muscular atrophy (SMA) patients across a range of trials.
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of statistically significant improvement of overall survival (OS) and composite complete remission rate (CR + CRi) for patients with previously-untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
Genentech has secured approval in the US to go ahead with the COVACTA trial to assess the use of its rheumatoid arthritis drug (RA drug) Actemra (tocilizumab) in COVID-19 patients.
Northwell Health’s Feinstein Institutes for Medical Research has announced the recruitment of patients in three clinical studies, which are designed to eliminate the COVID-19 novel coronavirus.
Roche has announced that it will begin a phase III clinical trial of Actemra/RoActemra (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia.
US pharma company Pfizer said that the phase 3 JADE COMPARE trial for abrocitinib in atopic dermatitis (AD) met its co-primary efficacy endpoints.
Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA (siRNA) investigational agent for hyperlipidemia in adults.
AstraZeneca said that Imfinzi (durvalumab) has been demonstrated to have delivered a sustained overall survival (OS) benefit in the final analysis of the phase 3 CASPIAN trial in extensive-stage small cell lung cancer.
Merck announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough.
Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.